Last reviewed · How we verify
CD1a-CAR T
At a glance
| Generic name | CD1a-CAR T |
|---|---|
| Sponsor | OneChain Immunotherapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (PHASE1)
- Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD1a-CAR T CI brief — competitive landscape report
- CD1a-CAR T updates RSS · CI watch RSS
- OneChain Immunotherapeutics portfolio CI